Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.

ABSTRACT:

Background

Obesity affects over one billion people worldwide and is associated with ocular complications, yet comparative effects of newer anti-obesity medications on eye health remain poorly understood. We examine ocular health outcomes among individuals with obesity receiving Tirzepatide, Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, or Phentermine monotherapy.

Methods

This propensity-score matched cohort study analyzed TriNetX US network data from November 2023 through April 2025. The study included matched pairs of obese individuals with a BMI ≥ 27 kg/m², comparing ocular outcomes between different anti-obesity medications. Primary outcomes included cataracts, oculomotor binocular dysfunction, visual disturbances, dry eye disease, ametropic accommodative dys

SUBMITTER: Huang YN 

PROVIDER: S-EPMC12316913 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature